Enochian Biosciences Announces FDA INTERACT Meeting for a Potential Cure for HIV
February 24 2020 - 7:30AM
Enochian Biosciences, a company focused on genetically modified
cellular and immune therapy for infectious diseases and cancer,
announces that the FDA has scheduled an Initial Targeted Engagement
for Regulatory Advice on CBER Products (INTERACT) meeting for early
June. The meeting is focused on Enochian’s ENOB-HV-01, a
novel approach to autologous stem cell transplantation with the
potential to increase engraftment of genetically modified cells
that are resistant to HIV infection, as a potential cure for
HIV. The FDA’s Center for Biologics Evaluation and Research
(CBER) has numerous INTERACT requests and only grants meetings that
are deemed appropriate for this early FDA engagement. The INTERACT
meetings are a new program at CBER, FDA, as part of their
commitment to help accelerate the development and approval of
innovative medical products.
Forward-Looking Statements
Statements in this press release that are not
strictly historical in nature are forward-looking statements. These
statements are only predictions based on current information and
expectations and involve a number of risks and uncertainties,
including but not limited to the success or efficacy of our
pipeline or the results of any meeting with the FDA. All statements
other than historical facts are forward-looking statements, which
can be identified by the use of forward-looking terminology such as
“believes,” plans,” “expects,” “aims,” “intends” “potential” or
similar expressions. Actual events or results may differ materially
from those projected in any of such statements due to various
uncertainties, including as set forth in Enochian’s most recent
Annual Report on Form 10-K filed with the SEC. Readers are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. All
forward-looking statements are qualified in their entirety by this
cautionary statement and Enochian undertakes no obligation to
revise or update this press release to reflect events or
circumstances after the date hereof.
Contact:
ir@enochianbio.com
Enochian Biosciences (NASDAQ:ENOB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Enochian Biosciences (NASDAQ:ENOB)
Historical Stock Chart
From Apr 2023 to Apr 2024